101 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
, specializing in regulatory and clinical strategy, and therapeutic development for rare diseases.
In January 2024, we initiated the open label extension … and who can apply their experience toward meaningful contributions to our business strategy and oversight of our performance, risk management
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
may not ultimately agree with Larimar’s nomlabofusp development strategy; the potential impact of public health crises on Larimar’s future clinical
8-K
EX-99.3
LRMR
Larimar Therapeutics Inc
11 Mar 24
Other Events
4:09pm
, and assessments; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy; the potential impact of public health crises
8-K
EX-99.1
2dkm2m97i5xmvvwr
11 Mar 24
Other Events
4:09pm
8-K
EX-99.2
rf3kqyau7edp3ajh
11 Mar 24
Other Events
4:09pm
424B5
g65uiv
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
m865s8pr
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
t57i73w19 s1beb
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.3
4i6rtts1kj5tp 1e7ew
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
671be36jcs8ngl6 y2
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
597g9i3y pk35b
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
424B5
pg1 ogrmfjvc
14 Sep 22
Prospectus supplement for primary offering
7:28am